Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.

Chinese medical journal - 1 Jan 2014

Sui Meijuan, Zhang Zhuo, Zhou Jin

Abstract excerpt

OBJECTIVE: To summarize limitations involved in arsenic trioxide therapeutic effects in acute promyelocytic leukemia, because current studies show that some individuals of acute promyelocytic leukemia have relatively poor outcomes during treatment with arsenic trioxide. DATA SOURCES: Most relevant articles were included in the PubMed database between 2000 and 2013 with the keywords "acute promyelocytic leukemia,"...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Arsenic Trioxide
Share to Arsenicals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Promyelocytic, Acute

Share to Mutation

Share to Oxides

Source

Identifiers

PMID: 25269921

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.PMID 25269921Read ↗

Molecular Targets of Arsenic Trioxide in Malignant CellsSemantic proximity Read ↗

Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.Semantic proximity Read ↗

Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemiaSemantic proximity Read ↗

Resistance to Arsenic Therapy in Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Treatment of Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkβ-dependent induction of hTERT due to down-regulation of Pin1 transcriptionSemantic proximity Read ↗

Curative Strategies in Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemiaSemantic proximity Read ↗

Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.Semantic proximity Read ↗

[Molecular basis of arsenic action in promyelocytic leukemia cells].Semantic proximity Read ↗

Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As2O3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.